Access to innovative drugs in Romania considered poor

…very few innovative drugs to the reimbursement list between 2013 and 2016, while the EMA (the European Medicines Agency) approved 156 at that time. The study also revealed that it takes a very long time to obtain a reimbursement decision in Romania.      

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.